[1]
|
A. Jemal, R. Siegel, E. Ward, et al., “Cancer Statistics, 2006,” CA: A Cancer Journal for Clinicians, Vol. 56, No. 2, 2006, pp. 106-130. doi:10.3322/canjclin.56.2.106
|
[2]
|
M. Fung-Kee-Fung, J. Dodge, L. Elit, H. Lukka, A. Chambers and T. Oliver, “Follow-Up after Primary Therapy for Endometrial Cancer: A Systematic Review,” Gynecologic Oncology, Vol. 101, No. 3, 2006, pp. 520-529.
doi:10.1016/j.ygyno.2006.02.011
|
[3]
|
W. T. Creasman, C. P. Morrow, B. N. Bundy, H. D. Homesley, J. E. Graham and P. B. Heller, “Surgical Pathologic Spread Patterns of Endometrial Cancer. A Gynecologic Oncology Group Study,” Cancer, Vol. 60, No. S8, 1987, pp. 2035-2041.
doi:10.1002/1097-0142(19901015)60:8+<2035::AID-CNCR2820601515>3.0.CO;2-8
|
[4]
|
W. A. Tjalma, P. A. van Dam, A. P. Makar and D. J. Cruickshank, “The Clinical Value and the Cost-Effectiveness of Follow-Up in Endometrial Cancer Patients,” International Journal of Gynecological Cancer, Vol. 14, No. 5, 2004, pp. 931-937.
doi:10.1111/j.1048-891X.2004.014532.x
|
[5]
|
E. Sartori, B. Pasinetti, L. Carrara, A. Gambino, F. Odicino and S. Pecorelli, “Pattern of Failure and Value of Follow-Up Procedures in Endometrial and Cervical Cancer Patients,” Gynecologic Oncology, Vol. 107, No. 1, 2007, pp. S241-S247. doi:10.1016/j.ygyno.2007.07.025
|
[6]
|
C. P. Morrow, B. N. Bundy, R. J. Kurman, et al., “Relationship between Surgical-Pathological Risk Factors and Outcome in Clinical Stage I and II Carcinoma of the Endometrium: A Gynecologic Oncology Group Study,” Gynecologic Oncology, Vol. 40, No. 1, 1991, pp. 55-65.
doi:10.1016/0090-8258(91)90086-K
|
[7]
|
I. Otsuka, M. Uno, A. Wakabayashi, S. Kameda, H. Udagawa and T. Kubota, “Predictive Factors for Prolonged Survival in Recurrent Endometrial Carcinoma: Implications for Follow-Up Protocol,” Gynecologic Oncology, Vol. 119, No. 3, pp. 506-510.
doi:10.1016/j.ygyno.2010.08.013
|
[8]
|
A. Berchuck, C. Anspach, A. C. Evans, et al., “Postsurgical Surveillance of Patients with FIGO Stage I/II Endometrial Adenocarcinoma,” Gynecologic Oncology, Vol. 59, No. 1, 1995, pp. 20-24. doi:10.1006/gyno.1995.1262
|
[9]
|
E. Podczaski, P. Kaminski, K. Gurski, et al., “Detection and Patterns of Treatment Failure in 300 Consecutive Cases of ‘Early’ Endometrial Cancer after Primary Surgery,” Gynecologic Oncology, Vol. 47, No. 3, 1992, pp. 323-327. doi:10.1016/0090-8258(92)90134-5
|
[10]
|
H. B. Salvesen, L. A. Akslen, T. Iversen and O. E. Iversen, “Recurrence of Endometrial Carcinoma and the Value of Routine Follow up,” BJOG: An International Journal of Obstetrics & Gynaecology, Vol. 104, No. 11, 1997, pp. 1302-1307. doi:10.1111/j.1471-0528.1997.tb10979.x
|
[11]
|
I. Otsuka, M. Uno, A. Wakabayashi, S. Kameda, H. Udagawa and T. Kubota, “Predictive Factors for Prolonged Survival in Recurrent Endometrial Carcinoma: Implications for Follow-Up Protocol,” Gynecologic Oncology, Vol. 119, No. 3, 2010, pp. 506-510.
doi:10.1016/j.ygyno.2010.08.013
|
[12]
|
Y. Ueda, T. Enomoto, T. Egawa-Takata, et al., “Endometrial Carcinoma: Better Prognosis for Asymptomatic Recurrences than for Symptomatic Cases Found by Routine Follow-Up,” International Journal of Clinical Oncology, Vol. 15, No. 4, pp. 406-412.
doi:10.1007/s10147-010-0080-7
|
[13]
|
A. G. Shumsky, G. C. Stuart, P. M. Brasher, J. G. Nation, D. I. Robertson and S. Sangkarat, “An Evaluation of Routine Follow-Up of Patients Treated for Endometrial Carcinoma,” Gynecologic Oncology, Vol. 55, No. 2, 1994, pp. 229-233. doi:10.1006/gyno.1994.1282
|
[14]
|
J. M. Reddoch, T. W. Burke, M. Morris, C. Tornos, C. Levenback and D. M. Gershenson, “Surveillance for Recurrent Endometrial Carcinoma: Development of a Follow-Up Scheme,” Gynecologic Oncology, Vol. 59, No. 2, 1995, pp. 221-225. doi:10.1006/gyno.1995.0012
|
[15]
|
P. Morice, C. Levy-Piedbois, S. Ajaj, et al., “Value and Cost Evaluation of Routine Follow-Up for Patients with Clinical Stage I/II Endometrial Cancer,” European Journal of Cancer, Vol. 37, No. 8, 2001, pp. 985-990.
doi:10.1016/S0959-8049(01)00066-1
|
[16]
|
O. O. Agboola, E. Grunfeld, D. Coyle and G. A. Perry, “Costs and Benefits of Routine Follow-Up after Curative Treatment for Endometrial Cancer,” CMAJ, Vol. 157, No. 7, 1997, pp. 879-886.
|
[17]
|
C. J. Smith, M. Heeren, J. L. Nicklin, et al., “Efficacy of Routine Follow-Up in Patients with Recurrent Uterine Cancer,” Gynecologic Oncology, Vol. 107, No. 1, 2007, pp. 124-129. doi:10.1016/j.ygyno.2007.06.002
|
[18]
|
J. R. Dijkstra, G. H. De Bock and M. J. Mourits, “The Clinical Value and the Cost-Effectiveness of Follow-Up in Endometrial Cancer Patients,” International Journal of Gynecological Cancer, Vol. 15, No. 5, 2005, pp. 991-992.
doi:10.1111/j.1525-1438.2005.00257.x
|